Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

John Mascarenhas, MD, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Ruben Mesa, MD, Rami S. Komrokji, MD, Steffen Koschmieder, MD, Alessandro M. Vannucchi, MD, Tymara Berry, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Libo Sun, PhD, Fei Huang, PhD, Ying Wan, PhD, Faye Feller, MD, Aleksandra Rizo, MD PhD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-138915

Published: 2020

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye Feller, MD, Tymara Berry, MD, Libo Sun, PhD, Ying Wan, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138818

Published: 2020

Journal Articles

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Tymara Berry, MD, Faye Feller, MD, Libo Sun, PhD, Ying Wan, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138905

Published: 2020

Journal Articles

Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye Feller, MD, Fei Huang, PhD, Aleksandra Rizo, MD PhD, Libo Sun, PhD, Ying Wan, PhD, Alessandro M. Vannucchi, MD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-138823

Published: 2020

Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux

Blood (2018) 132 (Supplement 1): 463.

https://doi.org/10.1182/blood-2018-99-114877

Published: 2018

Journal Articles

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, MD, Bruno Martino, MD, Dietger Niederwieser, MD, Andreas Reiter, MD, Bart L Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Jacqueline Bussolari, PhD, Eugene Zhu, PhD, Fei Huang, PhD, Esther Rose, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye M. Feller, MD, Jean-Jacques Kiladjian, MD PhD

Blood (2018) 132 (Supplement 1): 685.

https://doi.org/10.1182/blood-2018-99-115163

Published: 2018

Journal Articles

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Pierre Fenaux, MD PhD, Azra Raza, MD, Edo Vellenga, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Irina Samarina, MD, Koen Van Eygen, MD, Maria Díez-Campelo, MD PhD, Mrinal M. Patnaik, MDMBBS, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Aleksandra Rizo, MD PhD, David P. Steensma, MD

Blood (2017) 130 (Supplement 1): 4256.

https://doi.org/10.1182/blood.V130.Suppl_1.4256.4256

Published: 2017

NARROW

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only